Candriam unveils oncology impact fund

Eugenia Jiménez
clock
Candriam unveils oncology impact fund

Candriam has launched an equity strategy investing in listed companies that develop products and services for the treatment of cancer.

Candriam Equities L Oncology Impact expands Candriam's expertise in thematic investing, with existing biotech, robotics and demographic strategies representing over €3bn in assets under management.

The new Fund supports the development of a wide range of cancer diagnostics and treatments while seeks to identify those breakthrough innovations that are changing the way we treat cancer.

Candriam says that the Fund gives investors the opportunity to put their money into a fund which has a direct positive social impact. Also,10% of the management fees of the fund will support cancer research through leading European cancer research institutes.

The Candriam Equities L Oncology Impact, a sub-fund of Candriam Equities L, a Sicav (Société d'investissement à capital variable) domiciled in Luxembourg and managed by Candriam Luxembourg, is currently registered for marketing in Luxembourg, Austria, Switzerland, Germany, Spain, France, the UK, Italy, the Netherlands and Portugal.

Rudi Van den Eynde, Head of Thematic Equity, said: "We see a lot of innovation in the treatment of many diseases and particularly cancer. We want to identify those companies with strong growth potential. With its in-depth expertise, our team is very well positioned: it is rooted in 20 years' experience managing a dedicated biotech fund, it has two PhD level analysts and it will be backed by an independent advisory board with leading scientists in the oncology field."   

Vincent Hamelink, Chief Investment Officer - Investment Management, added: "As new treatments and next-generation technologies will further drive the worldwide oncology market growth, our new Candriam Equities L Oncology Impact is designed to generate a profit for investors while at the same time benefiting cancer research and having an impact on society. By broadening the scope of our commitments and pledging 10% of the fund's management fees, we seek to contribute even more tangibly to the fight against cancer."

Despite recent scientific advances, the outlook for people diagnosed with cancer is often still too poor. Cancer is the second-leading cause of death globally and 40% of all men and women will be diagnosed with cancer at some point during their lifetimes. Global ageing is fuelling the cancer epidemic as the disease mostly comes with age. Worldwide cancer deaths are projected to increase by 60% from 8 million to 13 million by 2030.

More on Equities

iM Global Partner rebrands Luxembourg-based Oyster fund range

iM Global Partner rebrands Luxembourg-based Oyster fund range

clock 10 January 2022 • 1 min read
Impax AUM exceeds £40bn at end of 2021

Impax AUM exceeds £40bn at end of 2021

Up 11.1% during ‘strong’ quarter

clock 10 January 2022 • 1 min read
Invesco looks to merge two Causer and Read income funds

Invesco looks to merge two Causer and Read income funds

Subject to shareholder approval

clock 07 January 2022 • 1 min read